Avalo Therapeutics AVTX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's operating lease liabilities (total)?
- Avalo Therapeutics (AVTX) reported operating lease liabilities (total) of $328K in Q1 2026.
- How has Avalo Therapeutics's operating lease liabilities (total) changed year-over-year?
- Avalo Therapeutics's operating lease liabilities (total) decreased by 59.1% year-over-year, from $801K to $328K.
- What is the long-term trend for Avalo Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Avalo Therapeutics's operating lease liabilities (total) has grown at a -21.8% compound annual growth rate (CAGR), from $1.46M to $427K.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.